EIM
CRSP icon

Essex Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Essex Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-266
Closed -$12.1K – 339
2023
Q3 		$12.1K Hold
266
– – ﹤0.01% 342
2023
Q2 		$14.9K Sell
266
-215
-45% -$12.2K ﹤0.01% 349
2023
Q1 		$21.8K Hold
481
– – ﹤0.01% 343
2022
Q4 		$20K Sell
481
-17,701
-97% -$939K ﹤0.01% 347
2022
Q3 		$1.19M Buy
18,182
+5,668
+45% +$411K 0.19% 159
2022
Q2 		$760K Sell
12,514
-18,297
-59% -$1.08M 0.12% 219
2022
Q1 		$1.93M Sell
30,811
-2,017
-6% -$127K 0.24% 128
2021
Q4 		$2.49M Sell
32,828
-1,146
-3% -$100K 0.28% 107
2021
Q3 		$3.8M Buy
33,974
+138
+0.4% +$17.3K 0.47% 58
2021
Q2 		$5.48M Sell
33,836
-1,704
-5% -$207K 0.64% 42
2021
Q1 		$4.33M Buy
+35,540
New +$5.37M 0.53% 45
2020
Q4 		– Sell
-41,966
Closed -$3.51M – 484
2020
Q3 		$3.51M Sell
41,966
-60
-0.1% -$5.32K 0.5% 47
2020
Q2 		$3.09M Sell
42,026
-9,345
-18% -$546K 0.51% 53
2020
Q1 		$2.18M Sell
51,371
-32,077
-38% -$1.66M 0.44% 60
2019
Q4 		$5.08M Buy
83,448
+4,629
+6% +$253K 0.62% 30
2019
Q3 		$3.23M Sell
78,819
-6,780
-8% -$324K 0.47% 52
2019
Q2 		$4.03M Buy
+85,599
New +$3.42M 0.55% 36
2018
Q3 		– Sell
-40,939
Closed -$2.41M – 411
2018
Q2 		$2.41M Buy
40,939
+19,149
+88% +$1.09M 0.3% 101
2018
Q1 		$996K Sell
21,790
-29,290
-57% -$1.21M 0.13% 208
2017
Q4 		$1.2M Buy
+51,080
New +$971K 0.16% 198

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Essex Investment Management's CRSP Position: Q4 2023 in Review

Essex Investment Management sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 266 shares — an estimated $12.1K sold.

Essex Investment Management first reported a position in CRSP in Q4 2017 and held it in 20 quarters. The position peaked at $5.48M in Q2 2021. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

  • Essex Investment Management reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Essex Investment Management sold 266 CRISPR Therapeutics shares in Q4 2023, an estimated $12.1K.
  • Essex Investment Management first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 20 quarters.
  • Essex Investment Management's CRISPR Therapeutics position peaked at $5.48M in Q2 2021.
  • 472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Essex Investment Management's 13F filing for Q4 2023, filed 8 Feb 2024.